CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora

Loading news article.

CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora | WAPE

CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora

Article summary

Related companies

Comments —